Compare FDBC & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDBC | BDSX |
|---|---|---|
| Founded | 1902 | 2005 |
| Country | United States | United States |
| Employees | 324 | N/A |
| Industry | Major Banks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.4M | 153.3M |
| IPO Year | 2000 | 2020 |
| Metric | FDBC | BDSX |
|---|---|---|
| Price | $53.35 | $27.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 12.5K | ★ 119.9K |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | ★ 35.00 | N/A |
| EPS | ★ 2.63 | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | $20.25 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $39.87 | $0.35 |
| 52 Week High | $56.14 | $31.31 |
| Indicator | FDBC | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 53.35 | 59.35 |
| Support Level | $49.82 | $19.26 |
| Resistance Level | $56.14 | N/A |
| Average True Range (ATR) | 1.00 | 2.42 |
| MACD | -0.25 | 0.37 |
| Stochastic Oscillator | 25.44 | 60.53 |
Fidelity D & D Bancorp Inc is a bank holding company. Through its wholly-owned state chartered commercial bank subsidiary, The Fidelity Deposit and Discount Bank (the Bank), the company provides a full range of banking, trust and financial services to individuals, small businesses and corporate customers. Its primary market areas are Lackawanna, Luzerne and Northampton Counties, Pennsylvania. The company's primary deposit products are demand deposits and interest-bearing time, money market and savings accounts. The company's segments include: Commercial and Industrial, Commercial Real Estate, Consumer, Residential Real Estate, with the majority of revenue generating from the Commercial Real Estate segment.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.